1274
Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "retinoic acid syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis.
 ( adverse event: developed ,  a patient with APL: Subject, symptom complex referred to as "retinoic acid syndrome.": Effect, a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis: Treatment, ATRA: Treatment.Drug, a few weeks: Treatment.Time_elapsed, APL: Treatment.Disorder) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: developed ,  a patient with APL: Subject, symptom complex referred to as "retinoic acid syndrome.": Effect, a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis: Treatment, ATRA: Treatment.Drug, a few weeks: Treatment.Time_elapsed, APL: Treatment.Disorder) 